Melanotan 2: Sunless Tanning & E.D. Why it never become an approved pharmaceutical.
Melanotan is one of the more recognizable peptide names, mostly because of its association with sunless tanning. What's less well known is that "Melanotan" actually refers to two distinct compounds with genuinely different safety profiles and entirely different regulatory fates, and that the research behind both eventually produced two FDA-approved drugs that most people have never connected back to the tanning peptide they started from.
This post covers the mechanism, the actual use cases people pursue, the documented side effects, and the cautions that I think are genuinely important to understand before considering this compound — because the adverse event profile here is more serious than most.
The Backstory: One Lab, Two Molecules, Two Fates
Both Melanotan compounds came out of research at the University of Arizona in the 1980s and 1990s, built on a natural hormone called alpha-melanocyte-stimulating hormone (α-MSH) — a peptide your body already produces that regulates skin pigmentation, among other things.
Researchers created two synthetic analogs:
Melanotan I, a linear peptide that's highly selective for one specific receptor (MC1R, the pigmentation receptor).
Melanotan II, a cyclic (ring-shaped) peptide that activates four different receptors in the same family — MC1R, MC3R, MC4R, and MC5R — without much selectivity between them.
That single structural difference — linear and selective vs. cyclic and non-selective — explains almost everything about why these two compounds ended up in completely different places.
Melanotan I was licensed to an Australian pharmaceutical company, went through a full clinical trial program, and in October 2019 was FDA-approved under the brand name Scenesse for a rare genetic condition called erythropoietic protoporphyria (EPP) — a disorder where sunlight exposure causes severe, burning pain. It's administered as a controlled-release implant by a physician, has over a decade of safety data across more than a thousand patients, and remains approved today, specifically for that one indication.
Melanotan II never made it through clinical development as a standalone drug. During early human trials in the 1990s, researchers noticed an unexpected effect: spontaneous erections in male volunteers. That finding redirected the research entirely — the team isolated the receptor responsible (MC4R) and developed a more selective derivative, which eventually became bremelanotide, FDA-approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women.
Melanotan II itself was set aside. The same broad receptor activity that produced the unexpected arousal finding also meant it came with a wider range of side effects that made it unsuitable as a clean pharmaceutical candidate. It was never submitted for FDA approval and has no regulatory approval anywhere in the world. What happened instead is what tends to happen to compounds in this position: it leaked into the unregulated online market, where it remains available today, sold under research-use-only labeling, primarily for cosmetic tanning.
This is the most important thing to understand before anything else in this post: when people talk about "Melanotan" in the tanning context, they are almost always talking about Melanotan II — the compound that was never approved, not its FDA-approved cousin.
How It Actually Works
The mechanism runs through the melanocortin receptor system — a family of five G-protein-coupled receptors (MC1R through MC5R) found in different tissues throughout the body, each controlling different physiological functions.
MC1R sits on melanocytes, the pigment-producing cells in your skin. When activated, it triggers a signaling cascade that ramps up production of eumelanin — the brown-black pigment responsible for tanning. This is the pathway both Melanotan compounds were originally designed to target, and it's genuinely effective: skin darkens measurably, independent of UV exposure, though the effect compounds with sun exposure rather than replacing the need for sun protection entirely.
MC3R and MC4R sit primarily in the brain and hypothalamus, and this is where Melanotan II's non-selectivity creates its broader (and more complicated) effects. MC4R activation triggers dopamine release in brain regions governing sexual arousal — this is the mechanism behind the spontaneous erections and increased libido reported with use. The same receptor pathway is also involved in appetite regulation, which is why appetite suppression is commonly reported.
MC5R is involved in exocrine gland function and some additional metabolic and immune effects that are less well characterized.
Melanotan I, by contrast, largely stays in its lane — it's selective enough for MC1R that the central nervous system effects (arousal, appetite suppression) are minimal to absent. This is part of why it was a viable pharmaceutical candidate and Melanotan II wasn't: a drug that does one predictable thing is much easier to get through regulatory approval than one that does four different things simultaneously, some of which weren't intended.
What People Actually Use It For
Cosmetic tanning is the dominant use case for Melanotan II, and it's the reason most people encounter the compound at all. The appeal is straightforward: a tan without UV exposure, marketed especially toward people with fair skin who tan poorly or burn easily, or those wanting a base tan before an event. Visible darkening typically begins within 3–7 days of starting use, with a peak effect around 2–4 weeks. The tanning effect is cumulative — each dose adds incrementally to total pigmentation — and unlike a sunburn-driven tan, it doesn't require UV damage to occur, though many users combine it with sun or tanning bed exposure to accelerate and deepen the effect.
Libido and sexual function is a secondary but commonly cited use, given the MC4R-driven arousal effect documented since the original 1990s trials. This is the mechanism that eventually produced bremelanotide (Vyleesi) as an approved, more targeted alternative — which is worth knowing if this is your primary interest, since it offers a regulated pathway with a better-characterized safety profile for that specific effect.
Appetite suppression gets mentioned periodically, but it's a secondary effect rather than a primary one, and it's considerably weaker than dedicated appetite-suppressing compounds like GLP-1 medications. Nobody using Melanotan II as their main strategy for weight management is using the most effective tool available for that goal.
Side Effects: What's Actually Documented
This is the section that deserves the most careful attention, because the side effect profile for Melanotan II is broader and in some cases more serious than most compounds covered in this newsletter.
The common, dose-limiting effects reported in the original human studies and consistently since: nausea and flushing, particularly with the first several doses as the body adjusts. These are uncomfortable but generally not dangerous, and many users report they diminish with continued use.
Spontaneous erections and increased sexual arousal occur via the MC4R mechanism described above, for some users a desired effect, for others an unwanted one, and notable enough that it has been documented since the compound's earliest trials.
Skin and mole changes are a meaningfully important category. Because the tanning mechanism works by stimulating melanocyte activity broadly, not just in unblemished skin, changes in the appearance of existing moles and the eruption of new pigmented lesions (dysplastic nevi) have been documented in published case reports. A case report on oral mucosa changes associated with Melanotan II use documented pigmentation changes inside the mouth as well — a reminder that the compound's effect on melanocytes isn't limited to visible skin.
The melanoma question is the one that warrants the most direct caution. Multiple published case reports have associated Melanotan II use with melanoma diagnosis. To be precise about what the evidence does and doesn't establish: several studies in the literature have explored a potential association between Melanotan use and melanoma development, but conclusive evidence confirming a direct causal relationship remains lacking. That's an important distinction - case reports demonstrate association and temporal correlation, not proof that the compound causes melanoma. But the mechanism is biologically plausible (stimulating melanocyte activity broadly is not obviously a neutral act for cells that, when they go wrong, become melanoma), and the case report volume is large enough that dermatologists treat it as a genuine concern rather than a coincidental pattern. Anyone with a personal or family history of melanoma, dysplastic nevus syndrome, or a high mole count should consider this a significant relative contraindication, not a minor caveat.
More severe documented adverse events, reported in published case literature: priapism (a prolonged, painful erection requiring emergency medical intervention, including surgery in some cases), rhabdomyolysis (breakdown of muscle tissue that can cause kidney damage), renal infarction, and posterior reversible encephalopathy syndrome. These are serious, hospital-level events. They are not the typical or expected experience for most users, but their presence in the published case report literature means they are real, documented outcomes that have occurred - not theoretical possibilities.
Hormonal and metabolic effects have also been documented, including an association between tanning injection use and hypercortisolism, hyperglycemia, and ketosis specifically in a patient with Type 1 diabetes - a reminder that the broad receptor activity of MT-II can interact meaningfully with existing endocrine conditions.
A Note on Melanotan I and Why It's Different
If tanning specifically is the goal and the broader receptor activity of Melanotan II is the concern, it's worth understanding that Melanotan I (the FDA-approved Scenesse formulation) exists in a meaningfully different risk category - better receptor selectivity, minimal central nervous system effects, and over a decade of monitored safety data, albeit for a specific rare disease population rather than cosmetic use.
The caveat: Scenesse is approved specifically for EPP, administered by a physician as a controlled implant, and is not legally available or intended for cosmetic tanning. Off-label use would be a physician's prescribing decision, not something available through the unregulated peptide market. "Melanotan I" products sold online through research-chemical vendors are not the same regulated, quality-controlled product as Scenesse - they are unregulated, unverified formulations sold under the same name, with none of the manufacturing oversight that makes the approved product's safety data meaningful.
Regulatory Status
Melanotan II has no approval from the FDA, the European Medicines Agency, or any other major regulatory body, in any jurisdiction, for any indication. It exists in an unusual regulatory position even relative to other unapproved peptides - it sits outside the FDA's formal compounding bulk substance categorization system, but it has attracted direct regulatory enforcement attention. The UK's MHRA, for example, has issued direct public warnings to both consumers and vendors about Melanotan II specifically. Products sold online as "research use only" are, as with everything in this category, unregulated and quality-unverified.
Afamelanotide (Scenesse/Melanotan I) is FDA and EMA-approved, but strictly for EPP, available only through specialist prescribers, and not legally obtainable or intended for cosmetic use.
Bremelanotide (Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women and represents the regulated pathway for the libido-related mechanism that Melanotan II's off-target activity originally revealed.
The Bottom Line
The melanocortin receptor system that Melanotan targets is real, well-characterized biology, and the fact that two FDA-approved drugs (Scenesse and Vyleesi) emerged from this same research lineage is a genuine validation of the underlying pharmacology — this isn't speculative science.
But Melanotan II specifically - the compound most people mean when they say "Melanotan," and the one actually circulating in the cosmetic tanning market - was set aside during drug development precisely because its broad, non-selective receptor activity produced a side effect profile that couldn't be resolved into a clean, approvable drug. That's not an oversight or a regulatory technicality. It's the central reason this compound exists in the unregulated market today rather than as an approved tanning treatment.
The documented adverse event spectrum - melanoma association (correlational, not proven causal, but taken seriously by dermatologists), priapism, rhabdomyolysis, renal complications - is more serious than most of what's discussed in this newsletter, and the cosmetic motivation behind most use (tanning) is also lower-stakes than the therapeutic motivations behind compounds like BPC-157 for injury recovery. That combination - a meaningfully serious risk profile in search of a cosmetic goal, is worth really considering, rather than glossing over it.
If skin tanning is the goal, the evidence-based, zero-systemic-risk option remains what it's always been: physical sunless tanning products (DHA-based self-tanners) that work topically without any receptor activity or systemic absorption at all. They're less interesting to write about, but they don't carry any of the risk profile described above.
If sexual desire concerns are the actual motivation, bremelanotide (Vyleesi) represents the regulated, FDA-approved pathway for that specific mechanism, with a prescriber's oversight, and is a meaningfully different risk conversation than sourcing Melanotan II from an unregulated vendor.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Melanotan II is not approved for human use by any regulatory body and carries documented serious adverse event risks. Afamelanotide (Scenesse) and bremelanotide (Vyleesi) are FDA-approved prescription medications for specific indications and require a physician's prescription. Always consult a qualified healthcare provider, and a dermatologist specifically if you have any personal or family history of melanoma or atypical moles, before considering any melanocortin receptor agonist.